Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP

Anika Therapeutics, Inc. ANIK

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$112.8M
▼ 5.9% YoY
$-10.9M
$4.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Anika Therapeutics manufactures its OA Pain Management, Regenerative Solutions and other hyaluronic acid-based products at its facility in Bedford, Massachusetts. As of December 31, 2025, the company employed 235 full-time employees in the United States and Europe. In 2025, 2024 and 2023, the company's research and development expenses were $25.8 million, $25.5 million and $21.8 million, respectively. Its OA Pain Management product family consists of Orthovisc, Monovisc, and Cingal. Its Regenerative Solutions family includes Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments, designed to protect injured tendons and promote healing in rotator cuff repair and other tendon procedures. Anika Therapeutics, Inc. was founded in 1992.

Written from the business description in Anika Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 3 March 2026. Every sentence was checked against that document before publication.

Growth

USD 112.8M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 112.8 · Net income -10.9
100M200M-30M-60M
2009201220152018202120242025
Compound annual growth
−0.3%
−2.9%
+2.0%
+4.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −2.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−10 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -9.8% · Net -9.6%
20%40%-20%-40%-60%
200920172025
ROE
FY2025 · ROE -7.3%
10%20%-10%-20%-30%
200920172025
Three returns, three denominators.

Each USD of equity lost 7 cents this year.

Cash & shareholders

USD 9.5M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 4.4
15M30M-3M-6M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 9.5
10M20M
201620182019202020212022202320242025

USD 9.5M in buybacks went back to shareholders in a year without profit.

Total assetsUSD 190.3M
EquityUSD 143.5M
CashUSD 57.5M
Current ratio4.72×

Equity funds 75% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
ANIK, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.10.0
Operating income $B−0.0−0.00.00.00.0−0.00.00.00.00.10.00.10.00.00.00.00.0
EBITDA $B−0.0−0.00.00.00.0−0.00.00.00.00.10.10.10.00.00.00.00.0
Income tax $B0.00.00.00.0−0.0−0.00.00.00.00.00.00.00.00.00.00.00.0
Net income $B−0.0−0.1−0.1−0.00.0−0.00.00.00.00.00.00.00.00.00.00.00.0
Free cash flow $B0.0−0.0−0.0−0.00.00.00.00.00.00.00.00.00.00.00.00.0−0.0
EPS, diluted $−0.76−3.83−5.64−1.020.28−1.691.891.272.112.152.012.511.390.820.620.320.32
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %−7.3−30.8−33.2−5.21.5−8.69.97.113.115.015.824.416.811.59.45.24.5
Shares out B0.010.010.010.010.010.010.010.010.010.010.020.010.010.010.010.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 74 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image